Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development [...
Mural Oncology plc - Ordinary Shares (MURA)
Company Research
Source: Yahoo! Finance
potent and durable immune response, today announced the appointments of Jeltje Schulten, M.D., MBA, as SVP of clinical and medical affairs and Rita Dalal, MBBS, MPH, as vice president of clinical development. "With our first-in-class EGFR/TGF-ß-trap bifunctional antibody, BCA101, advancing in the clinic for HPV-negative, recurrent/metastatic head and neck squamous cell carcinoma and other solid tumor types, this is an important period of clinical development execution for Bicara," said Claire Mazumdar, Ph.D., MBA, chief executive officer of Bicara Therapeutics. "We are very pleased to welcome Jeltje and Rita to our talented team. They each bring significant oncology drug development expertise across multiple solid tumor types and we are confident that their collective skillset will help us to further accelerate and expand the BCA101 program to reach patients in need." Jeltje Schulten, M.D., MBA, as Senior Vice President, Clinical and Medical Affairs Dr. Jeltje Schulten is an acc
Show less
Read more
Impact Snapshot
Event Time:
MURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MURA alerts
High impacting Mural Oncology plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MURA
News
- Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual MeetingGlobeNewswire
- Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
MURA
Sec Filings
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- 5/8/24 - Form SC
- MURA's page on the SEC website